Abstract P4-14-05: Confirmation of the TAILORx 21-gene expression trial using a real world observational database
Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Treatment of High Risk DLBCL with DA-R-EPOCH in Those Unable to Tolerate Intensive Chemotherapy: Well-Tolerated and Effective, but Inadequate in Double/Triple Hit or Expressing DLBCL
Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL)
Early economic benefits of gene expression profiling using a 21-gene panel among patients with early stage, lymph node negative, hormone receptor positive, her2-neu oncogene negative breast cancer
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care
